Fractyl Health to Present Preclinical Proof-of-Concept Data for Rejuva® Pancreatic Gene Therapy Platform Program at the American Society of Gene & Cell Therapy Congress
LEXINGTON, Mass.--(BUSINESS WIRE)-- #diabetesawareness--Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering new approaches to the treatment of type 2 diabetes (T2D), announced today that it will be presenting two oral presentations describing its Rejuva® pancreatic gene therapy platform at the American Society of Gene & Cell Therapy (ASGCT)...
